Fullife Healthcare Lands ₹300 Cr From Elev8 to Boost Supplement Business

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Fullife Healthcare Lands ₹300 Cr From Elev8 to Boost Supplement Business
Overview

Fullife Healthcare has secured ₹300 crore from Elev8 and its affiliated investors. The funding comprises new capital and secondary purchases, intended to boost the company's leadership in effervescent nutritional supplements. Khaitan & Co provided legal advice for the deal.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Fueling Expansion in Nutritional Supplements

Fullife Healthcare has secured ₹300 crore from Elev8 and its affiliated investors. The funding comprises ₹150 crore in new equity for the company and ₹150 crore from secondary purchases, which offers liquidity for some existing shareholders.

Strengthening Market Leadership

This investment is set to boost Fullife Healthcare's leading position in India's effervescent nutritional supplement market. The company is already the largest manufacturer and supplier of effervescent products. The capital will support expansion efforts, new product research, and broader market reach.

Legal Support for the Deal

Khaitan & Co acted as the legal advisor for Fullife Healthcare during the transaction. The firm assisted with reviewing and negotiating agreements, and managing the deal's completion.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.